Psychiatry’s next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Despite the widespread application of drug modelling in psychiatric research, the relative value of different models has never been formally compared in the same analysis. Here we compared the effects of five drugs (cannabis, psilocybin, amphetamine, ketamine and alcohol) in relation to psychiatric symptoms in a two-part subjective analysis. In the first part, mental health professionals associated statements referring to specific experiences, for example ‘I don’t bother to get out of bed’, to one or more psychiatric symptom clusters, for example depression and negative psychotic symptoms. This measured the specificity of an experience for a particular disorder. In the second part, individuals with personal experience with each of the above-listed drugs were asked how reliably each drug produced the experiences listed in part 1, both acutely and sub-acutely. Part 1 failed to find any experiences that were specific for negative or cognitive psychotic symptoms over depression. The best model of positive symptoms was psilocybin and the best models overall were the acute alcohol and amphetamine models of mania. These results challenge current assumptions about drug models and motivate further research on this understudied area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The varieties of religious experience: A study in human nature.
James, W. (1902) · doi:10.1037/10004-000 · Cited by 5,204
Kapur, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.13 · Cited by 2,813 · cited 2×
“This is in contrast to studies of acute administration of these drugs in a laboratory setting, in which positive psychotic symptoms are commonly reported (Krystal et al., 1994, Gouzoulis-Mayfrank et al., 2005, Morrison et al., 2009).”
BackgroundResultGriffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 3×
“It has been claimed that certain drugs can reliably produce spiritual-type experiences that are indistinguishable from spontaneously occurring spiritual experiences (Griffiths et al., 2006).”
BackgroundInfluentialPerceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia
Fletcher, P. C., & Frith, C. D. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2536 · Cited by 1,462
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723 · cited 1×
“, 2005); however, despite considerable historical interest (Osmond and Smythies, 1952), they have fallen out of favour in recent years, as focus has shifted more on to their therapeutic potential (Vollenweider and Kometer, 2010).”
BackgroundA Bayesian foundation for individual learning under uncertainty
Mathys, C. (2011) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2011.00039 · Cited by 655
D’Souza, D. C., Abi-Saab, W. M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., Gueorguieva, R., Cooper, T. B., & Krystal, J. H. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.006 · Cited by 617 · cited 1×
“THC has attracted special interest recently however, due to its putative psychotogenic properties (D’Souza et al., 2005) and evidence that it can produce marked positive symptoms in some people (Atakan et al.”
BackgroundFrom drugs to deprivation: A Bayesian framework for understanding models of psychosis
Corlett, P. R., Frith, C. D., & Fletcher, P. C. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1561-0 · Cited by 367 · cited 1×
“Auditory-verbal hallucinations are common in acute psychosis but very rare in drug states (Gouzoulis-Mayfrank et al., 1998), whereas anxious states engendering false inferences are much more common (Fletcher and Frith, 2009, Corlett et al., 2009, Mathys et al., 2011).”
Background
Cited by
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
“…et al., 2013), and there is a growing literature on human research with such drugs, including an increasing number of neuroimaging studies (Carhart-Harris et al., 2013b, 2015b; Muthukumaraswamy et al., 2013) and clinical trials (Bogenschutz et al., 2015; Carhart-Harris et al., 2016a;…”
BackgroundMethodSelf-citationDopamine and glutamate in schizophrenia: biology, symptoms and treatment
McCutcheon, R. A., Krystal, J. H., & Howes, O. D. (2020) · World Psychiatry · doi:10.1002/wps.20693 · Cited by 612
Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders
Vollenweider, F. X., & Preller, K. H. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0367-2 · Cited by 570
The paradoxical psychological effects of lysergic acid diethylamide LSD
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M., Williams, T. M., Williams, L. T., Underwood, R., Feilding, A., & Nutt, D. J. (2016) · Psychological Medicine · doi:10.1017/s0033291715002901 · Cited by 293
Self-citation
Metadata
- Authors
- Carhart-Harris, R., Brugger, S., Nutt, D., & Stone, J.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2013-06-19
- Volume
- 27
- Issue
- 9
- Pages
- 771-778
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W1982429022
- Cited by
- 41
- References
- 9
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Psychiatry’s next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders. https://app.cochat.ai/papers/10.1177/0269881113494107
- The paper
- Carhart-Harris, R., Brugger, S., Nutt, D., & Stone, J. (2013). Psychiatry’s next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders. Journal of Psychopharmacology. https://doi.org/10.1177/0269881113494107
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.